Consensus SOPHiA GENETICS SA Börse Stuttgart
Stocks
90B
CH1125843347
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.675 EUR | +15.35% |
|
+19.29% | +48.20% |
| 08-04 | SOPHiA GENETICS SA, Q2 2026 Earnings Call, Aug 04, 2026 | |
| 08-04 | Sophia Genetics SA and AstraZeneca Enter Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies | CI |
Evolution of the Average Target: SOPHiA GENETICS SA
Evolution of the Target Price: SOPHiA GENETICS SA
Changes in Analyst Recommendations: SOPHiA GENETICS SA
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | ||
| +15.24% | |||||
| +10.26% | |||||
| +25.25% | |||||
| +34.26% | |||||
| +77.87% | |||||
| +55.74% | |||||
| - | +50.17% | ||||
| - | - | +23.99% | |||
| +62.84% | |||||
| Average | +39.51% | |||||
| Weighted average by Cap. | +20.21% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| HC Wainwright | |
| RBC Capital Markets | |
| Morgan Stanley | |
| Credit Suisse | |
| BTIG | |
| JPMorgan Chase | |
| Cowen |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SOPH Stock
- 90B Stock
- Consensus SOPHiA GENETICS SA
Select your edition
All financial news and data tailored to specific country editions
